IL178205A - Polypeptide sequences involved in the modulation of a viral protein immune response suppressor - Google Patents

Polypeptide sequences involved in the modulation of a viral protein immune response suppressor

Info

Publication number
IL178205A
IL178205A IL178205A IL17820506A IL178205A IL 178205 A IL178205 A IL 178205A IL 178205 A IL178205 A IL 178205A IL 17820506 A IL17820506 A IL 17820506A IL 178205 A IL178205 A IL 178205A
Authority
IL
Israel
Prior art keywords
modulation
polypeptide sequence
viral proteins
sequence involved
protein
Prior art date
Application number
IL178205A
Other languages
English (en)
Hebrew (he)
Other versions
IL178205A0 (en
Original Assignee
Centre Nat Rech Scient
Roussy Inst Gustave
Univ Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Roussy Inst Gustave, Univ Paris Sud filed Critical Centre Nat Rech Scient
Publication of IL178205A0 publication Critical patent/IL178205A0/en
Publication of IL178205A publication Critical patent/IL178205A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL178205A 2004-03-30 2006-09-20 Polypeptide sequences involved in the modulation of a viral protein immune response suppressor IL178205A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (2)

Publication Number Publication Date
IL178205A0 IL178205A0 (en) 2006-12-31
IL178205A true IL178205A (en) 2015-05-31

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178205A IL178205A (en) 2004-03-30 2006-09-20 Polypeptide sequences involved in the modulation of a viral protein immune response suppressor

Country Status (14)

Country Link
US (2) US8178657B2 (enExample)
EP (1) EP1732585B1 (enExample)
JP (1) JP5060284B2 (enExample)
CN (1) CN1961001B (enExample)
AT (1) ATE472334T1 (enExample)
AU (1) AU2005229411B2 (enExample)
BR (1) BRPI0509497B1 (enExample)
CA (1) CA2561376C (enExample)
DE (1) DE602005022056D1 (enExample)
ES (1) ES2347445T3 (enExample)
IL (1) IL178205A (enExample)
MX (1) MXPA06011272A (enExample)
WO (1) WO2005095442A1 (enExample)
ZA (1) ZA200608178B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
WO2006103562A2 (en) 2005-03-30 2006-10-05 Centre National De La Recherche Scientifique (Cnrs) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
CA2749183C (en) 2009-01-09 2017-11-28 Marc Sitbon New receptor binding ligands, their use in the detection of cells with biological interest
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
US20130260394A1 (en) * 2010-09-17 2013-10-03 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
AU2012350258B2 (en) * 2011-12-07 2017-03-02 Centre National De La Recherche Scientifique Mutated lentiviral ENV proteins and their use as drugs
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
US9974852B2 (en) 2013-06-07 2018-05-22 Viroxis Sas Mutated non-primate lentiviral Env proteins and their use as drugs
EP3309178A4 (en) * 2015-06-11 2019-05-08 Keio University FUSION PROTEIN OR CONJUGATED PROTEIN, CARRIER FOR INTRA-CELLULAR DELIVERY, PARTICLE PEPTIDE, CELL MEMBRANE PERMEATION AMPLIFIER, DNA AND VECTOR
CA2999792A1 (en) * 2015-10-01 2017-04-06 Magdalena Janina LASKA Use of human derived immunosuppressive proteins and peptides as medicaments
JP7277466B2 (ja) 2017-09-01 2023-05-19 インプラザー エー・ペー・エス 疾患の予防および／または治療における使用のためのワクチン
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク． Ａｒｃベースのカプシドおよびその使用
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
CA3204201A1 (en) 2021-01-13 2022-07-21 Thierry Heidmann Measles-hiv or measles-htlv vaccine
AU2024256799A1 (en) 2023-04-21 2025-11-06 Inprother Aps Improved expression of surface-displayed antigens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0377842B1 (en) * 1988-12-13 1995-10-04 President And Fellows Of Harvard College Prototype FeLV isolates for use in disease models and vaccines
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
EP1224291A1 (en) * 1999-10-28 2002-07-24 Universite De Geneve Multiple sclerosis-related superantigen
CA2429755A1 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
BRPI0509497B1 (pt) 2022-07-19
MXPA06011272A (es) 2007-04-17
WO2005095442A8 (en) 2006-11-02
CN1961001A (zh) 2007-05-09
AU2005229411A1 (en) 2005-10-13
AU2005229411B2 (en) 2010-11-18
CN1961001B (zh) 2012-09-05
US8178657B2 (en) 2012-05-15
US20080008683A1 (en) 2008-01-10
DE602005022056D1 (de) 2010-08-12
JP2008506357A (ja) 2008-03-06
US8597657B2 (en) 2013-12-03
BRPI0509497A (pt) 2007-09-11
US20120189647A1 (en) 2012-07-26
EP1732585B1 (en) 2010-06-30
CA2561376A1 (en) 2005-10-13
IL178205A0 (en) 2006-12-31
ES2347445T3 (es) 2010-10-29
WO2005095442A1 (en) 2005-10-13
JP5060284B2 (ja) 2012-10-31
EP1732585A1 (en) 2006-12-20
ATE472334T1 (de) 2010-07-15
ZA200608178B (en) 2008-10-29
CA2561376C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
IL178205A0 (en) Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
SI1685243T1 (sl) Imortalizirane ptičje celične linije za produkcijo virusov
WO2006136084A8 (en) Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses
WO2009108274A3 (en) Methods and compositions for adeno-associated virus (aav) with hi loop mutations
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
DK1513937T3 (da) Fremgangsmåde til den samtidige produktion af multiple proteiner; vektorer og celler til anvendelse derved
WO2010132092A3 (en) Cytidine deaminase fusions and related methods
MY169472A (en) Refolding of recombinant proteins
ATE400656T1 (de) Mini-dystrophin nukleinsäure- und peptidsequenzen
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
MX2007007586A (es) Composiciones de proteinas de virus de gripe y metodos de uso de las mismas.
WO2021198706A3 (en) Coronavirus vaccines
MX2009006398A (es) Genotecas de proteinas de fusion de transferrina.
MX2009012326A (es) Peptidos de señalizacion.
WO2007053188A3 (en) Production of multivalent virus like particles
PH12022552935A1 (en) Stabilized coronavirus spike protein fusion proteins
DE60114018D1 (de) Von zellen präsentierte peptide
ATE478965T1 (de) Lentivirusvektoren und deren verwendung
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
WO2007047504A3 (en) Natriuretic peptide modified transferrin fusion proteins
MX2010000232A (es) Metodos mejorados para la formacion de enlaces disulfuro.
WO2005002501A3 (en) Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
WO2007061762A3 (en) Non-viral gene delivery complex
DE60330680D1 (de) Transferrin-fusionsproteinbibliotheken
WO2007055823A3 (en) Gpcr expressing cell lines and antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed